Related Experiment Videos
Heparins and venous thromboembolism: current practice and future directions
1Clinica Medica II, University of Padua, Italy. paoprand@tin.it
Thrombosis and Haemostasis
|August 7, 2001
Summary
Low-molecular-weight heparins (LMWH) offer effective and safe treatment for venous thromboembolism, especially in cancer patients and for outpatient care. LMWH demonstrates advantages over unfractionated heparin (UFH) in specific clinical scenarios.
Area of Science:
- Pharmacology
- Hematology
- Clinical Medicine
Background:
- Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH) are primary treatments for venous thromboembolism (VTE).
- UFH requires dose adjustment and monitoring (activated partial thromboplastin time), presenting challenges in clinical practice.
- LMWH offers fixed dosing and is increasingly utilized for VTE management.
Purpose of the Study:
- To compare the efficacy and safety of LMWH versus UFH in treating and preventing venous thromboembolic disorders.
- To evaluate the role of LMWH in specific patient populations, including cancer patients and those undergoing orthopedic surgery.
- To assess the utility of LMWH in outpatient settings and for extended thromboprophylaxis.
Main Methods:
- Review and comparison of clinical trial data comparing UFH and LMWH for VTE treatment and prophylaxis.
- Analysis of outcomes including therapeutic range achievement, mortality rates, safety profiles, and patient convenience.
- Inclusion of data on specific LMWH agents like enoxaparin and emerging agents like pentasaccharide.
Main Results:
- Subcutaneous LMWH is as effective and safe as adjusted-dose UFH for VTE treatment, with reduced mortality in cancer patients and suitability for outpatient management.
- High-dose prophylactic LMWH is more effective than UFH and oral anticoagulants for preventing postoperative venous thrombosis in major orthopedic surgery.
- LMWH and UFH show equal efficacy in preventing postoperative deep-vein thrombosis in cancer patients; enoxaparin demonstrated safety and efficacy in bedridden patients.
Conclusions:
- LMWH represents a valuable therapeutic option for venous thromboembolism, offering advantages in safety, efficacy, and patient convenience over UFH in various settings.
- LMWH is particularly beneficial for cancer patients and in postoperative prophylaxis following major orthopedic procedures.
- Further investigation into agents like pentasaccharide is ongoing to expand treatment and prevention strategies for thromboembolic disorders.